乳腺癌内分泌治疗新的研究结果对临床实践的影响  

Impact of New Research Results of Endocrine Therapy on Breast Cancer in Clinical Practice

作　　者：易文君[1] 黄石庭 YI Wen-jun(Department of Breast and Thyroid Surgery,the Second Xiangya Hospital,Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院乳甲外科,湖南长沙410011 [2]深圳市第三人民医院甲乳外科,广东深圳518100

出　　处：《医学与哲学（B）》2018年第3期15-17,共3页Medicine & Philosophy(B)

基　　金：2014年国家自然科学基金项目(81441084);2015年湖南省自然科学基金项目(2015jj4059)

摘　　要：乳腺癌内分泌治疗对于激素受体(HR)阳性患者是一种副作用小、疗效确切的手段,但内分泌治疗仍有许多困惑有待进一步研究。早期绝经前患者卵巢功能抑制(OFS)的选择对象、时机及疗程上;早期绝经后患者内分泌治疗是否在5年~10年的基础上继续延长;晚期乳腺癌内分泌治疗耐药深深困扰着乳腺科医生,解决内分泌耐药的问题将对临床实践产生巨大影响。本文就新的研究结果对以上的问题的临床实践的影响作一探讨。Endocrine therapy of breast cancer in patients is a mild side effect and curative method for hormone receptor positive patients.However,there is still considerable confusion in the endocrine treatment which needs further study to solve.The timing of initiation,treatment duration and object choice of ovarian function suppression(OFS)among early premenopausal patients;whether to prolonged endocrine therapy in early postmenopausal patients on the basis of 5 years^10 years;and endocrine resistance of the advanced breast cancer are a series of major problems faced by breast surgeons.To solve these problems the doctors will have a significant impact on clinical practice.This article discusses the influence of the latest study on clinical practice on the above issues.

关 键 词：乳腺癌 内分泌治疗 雌激素受体 

分 类 号：R737.9[医药卫生—肿瘤]